Allo Stem Cell Transplant for GATA2 Mutations
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Mutations in GATA2 or the MonoMAC Syndrome
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 144 patients (estimated)
- Sponsors
- National Cancer Institute (NCI)
- Tags
- Allogeneic Stem Cell Transplant, Chemotherapy, Radiation Therapy
- Trial Type
- Treatment
- Last Update
- 3 months ago
- SparkCures ID
- 1717
- NCT Identifier
- NCT01861106
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.